Analyzing the patent and trademark challenges faced by 503A compounding pharmacies.
Martha M. Rumore, PharmD, RPh, MS, LLM, Esq
Advertisement
Articles by Martha M. Rumore, PharmD, RPh, MS, LLM, Esq
FDA seeks to reduce diversion of pharmaceutical products via sales by unlicensed distributers and tighten up the supply chain by vetting trading partners.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
World Lung Cancer Day: Pharmacists Are Essential Across Prevention, Screening, and Treatment
2
A Pharmacist's Guide to Probiotics for Preventing Traveler’s Diarrhea
3
July 2026 in Pain Management: 10 Developments That Advanced and Challenged Patient Care
4
Five Solid Tumor Advances That Defined July 2026
5